August 22, 2026

Xianweida Ecnoglutide EECOH-2 Lancet, Chinese Peptide Pipeline Week, Capricor Deramiocel PDUFA, Hengrui HRS-4729 MAFLD

Xianweida ecnoglutide EECOH-2 Lancet publication. Chinese peptide pipeline: Gan & Lee, Xianweida, Wayne Biotech. Capricor deramiocel PDUFA. Hengrui HRS-4729.

4 stories · Covering clinical-trials, industry, regulatory

Editor's Note

Saturday's peptide news anchors on Chinese biotech pipeline expansion and one high-profile non-peptide FDA decision. The Lancet Diabetes & Endocrinology published Saturday August 22 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist that preferentially activates the cAMP signaling pathway over β-arrestin recruitment; the 52-week open-label non-inferiority trial across 52 Chinese hospitals compared ecnoglutide (0.6 mg or 1.2 mg once weekly) against dulaglutide 1.5 mg in adults with type 2 diabetes on metformin monotherapy, with both ecnoglutide doses meeting the non-inferiority endpoint on HbA1c reduction and both well tolerated. Chinese biotech peptide pipeline activity broadened across the week with Gan & Lee Pharmaceuticals initiating a Phase II clinical trial of GZR102 (basal insulin/GLP-1RA fixed-dose weekly formulation) on August 8, Xianweida registering XW003 Phase I clinical trial for adolescent obesity on August 8, Wayne Biotech WBD156 capsule advancing, and Fujian Genorup semaglutide pipeline expanding. Capricor Therapeutics (NASDAQ: CAPR) faces its PDUFA target action date Saturday August 22 for deramiocel in Duchenne muscular dystrophy cardiomyopathy following the July 29 FDA Cellular, Tissue, and Gene Therapies Advisory Committee 9-3 vote against approval; a Complete Response Letter is the expected outcome. And Hengrui Pharma disclosed a CDE implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease and hepatitis (MAFLD/hepatitis), extending its cardiometabolic pipeline into the growing MASH commercial category anchored by Madrigal's Rezdiffra and Novo Nordisk's Wegovy MASH indication.

Clinical Trials

The Lancet Diabetes & Endocrinology Published Saturday August 22, 2026 the Full EECOH-2 Phase 3 Trial Results for Xianweida's Ecnoglutide (XW003), a First-in-Class cAMP-Biased GLP-1 Receptor Agonist That Preferentially Activates the cAMP Signaling Pathway Over β-Arrestin Recruitment; The 52-Week Open-Label Non-Inferiority Trial Across 52 Chinese Hospitals Compared Ecnoglutide (0.6 mg or 1.2 mg Once Weekly Subcutaneous Injection) Against Dulaglutide 1.5 mg in Adults With Type 2 Diabetes and Elevated Glucose Concentrations on Metformin Monotherapy; Both Ecnoglutide Doses Met the Non-Inferiority Endpoint on HbA1c Reduction, and Both Were Well Tolerated; The Biased-Agonism Concept (Selective Signaling Pathway Activation Rather Than Full Receptor Engagement) Has the Potential to Separate Efficacy From Side Effects in the GLP-1 Class

The Lancet Diabetes & Endocrinology published Saturday August 22, 2026 the full EECOH-2 Phase 3 trial results for Xianweida's ecnoglutide (XW003), a first-in-class cAMP-biased GLP-1 receptor agonist. Mechanism: ecnoglutide preferentially activates the cAMP intracellular signaling pathway over β-arrestin recruitment when it binds the GLP-1 receptor. This biased-agonism concept selects one downstream signaling arm over the other, with the theoretical potential to separate the therapeutic effects (glucose lowering via cAMP-mediated insulin secretion) from the side-effect burden (some of which may be β-arrestin-mediated). Trial design: 52-week open-label non-inferiority Phase 3 across 52 Chinese hospitals. Adults aged 18-75 years with BMI 20-35 kg/m2, type 2 diabetes diagnosis, and elevated glucose concentrations on metformin monotherapy. Randomized to subcutaneous ecnoglutide 0.6 mg or 1.2 mg once weekly, or dulaglutide 1.5 mg once weekly (active comparator). Primary results: both ecnoglutide doses met the non-inferiority endpoint on HbA1c reduction versus dulaglutide 1.5 mg. Both doses were well tolerated with a safety profile broadly consistent with the GLP-1 receptor agonist class. Ecnoglutide is the first global cAMP-biased GLP-1 receptor agonist to reach Phase 3 publication. The biased-agonism approach could inform next-generation GLP-1 drug design and offers a differentiated tolerability profile if the concept holds in larger populations.

#xianweida #ecnoglutide #xw003 #cAMP-biased-glp-1 #biased-agonism #eecoh-2 #lancet-diabetes-endocrinology #phase-3 #dulaglutide-comparison #type-2-diabetes #chinese-biotech #non-inferiority

Industry

Chinese Biotech Peptide Pipeline Expanded Across the Week With Gan & Lee Pharmaceuticals Initiating a Phase II Clinical Trial of GZR102 (a Basal Insulin/GLP-1RA Fixed-Dose Weekly Formulation) on August 8, 2026 and Registering a Phase I Study of GZR18 on August 15; Xianweida Registered XW003 (Ecnoglutide) Phase I Clinical Trial for Adolescent Obesity on August 8; Wayne Biotech WBD156 Capsule Advanced Through Development; Fujian Genorup Semaglutide Pipeline Expanded; The Week's Pattern Extends the Chinese Biotech GLP-1 Ambition That Now Spans Ribupatide (Hengrui-Kailera, Global Phase 3 H1 2027), Mazdutide (Innovent, GLP-1/Glucagon Dual Agonist in Late-Stage Trials), MWN105 (Minwei Bio, Semaglutide-Intolerant Population), and IBI3032 (Innovent, FDA IND August 5)

Chinese biotech peptide pipeline expanded across the week ending August 22, 2026. Key registrations and advances: Gan & Lee Pharmaceuticals initiated a Phase II clinical trial of GZR102 (a basal insulin plus GLP-1 receptor agonist fixed-dose weekly formulation) on August 8, targeting patients requiring both basal glycemic control and appetite-and-glucose modulation from a single weekly injection; Gan & Lee also registered a Phase I study of GZR18 on August 15. Xianweida registered XW003 (ecnoglutide) Phase I clinical trial for adolescent obesity on August 8, extending the ecnoglutide franchise into pediatric obesity development after the adult Phase 3 EECOH-2 win. Wayne Biotech WBD156 capsule (oral peptide candidate) advanced through preclinical/early-clinical development. Fujian Genorup's semaglutide pipeline expanded across multiple formulation and indication programs. The week's pattern extends the broader Chinese biotech GLP-1 pipeline expansion that now spans ribupatide (Hengrui-Kailera, once-weekly injectable GLP-1/GIP/glucagon triple agonist, global Phase 3 planned H1 2027), mazdutide (Innovent, GLP-1/glucagon dual agonist in late-stage Chinese and US trials), MWN105 (Minwei Bio, targeting semaglutide-intolerant populations), IBI3032 (Innovent, FDA IND clearance August 5), and multiple additional candidates. The synchronized China+US development pattern reflects the increasing sophistication of Chinese biotech clinical strategy targeting global markets rather than China-only launches.

#chinese-biotech #peptide-pipeline #gan-lee #gzr102 #gzr18 #xianweida #xw003 #adolescent-obesity #wayne-biotech #wbd156 #fujian-genorup #basal-insulin-glp-1-fixed-dose #china-glp-1-expansion

Regulatory

Capricor Therapeutics (NASDAQ: CAPR) Faces Its Prescription Drug User Fee Act (PDUFA) Target Action Date Saturday August 22, 2026 for Deramiocel (a Cardiosphere-Derived Cell Therapy) in the Treatment of Duchenne Muscular Dystrophy (DMD) Cardiomyopathy Following the July 29 FDA Cellular, Tissue, and Gene Therapies Advisory Committee 9-3 Vote Against Approval, With Panel Members Citing Concerns About the Stability of the Statistical Results and How Missing Data Were Handled in the Phase 3 HOPE-3 Trial Left Ventricular Ejection Fraction (LVEF) Endpoint Analysis; A Complete Response Letter (CRL) Is the Expected Outcome, and Would Mark the Second CRL for Deramiocel Following the July 2025 Initial Rejection That Also Cited Inadequate Substantial Evidence of Effectiveness

Capricor Therapeutics (NASDAQ: CAPR) faces its Prescription Drug User Fee Act (PDUFA) target action date Saturday August 22, 2026 for deramiocel (a cardiosphere-derived cell therapy, not a peptide) in the treatment of Duchenne muscular dystrophy (DMD) cardiomyopathy. Background: the FDA issued a Complete Response Letter (CRL) in July 2025 citing that the Phase 2 data supporting the cell therapy fell short of the statutory requirement for substantial evidence of effectiveness. Capricor reported positive Phase 3 HOPE-3 trial results in December 2025 meeting both primary and secondary endpoints, and the FDA accepted the resubmission in March 2026 with a Class 2 resubmission classification and August 22 target action date. The July 29, 2026 FDA Cellular, Tissue, and Gene Therapies Advisory Committee voted 9-3 that available evidence does not provide substantial evidence of effectiveness to recommend approval. Panel members cited concerns about the stability of the statistical results, saying that left ventricular ejection fraction (LVEF) endpoint outcomes appeared highly sensitive to how missing data were handled and which analytic assumptions were applied. A second Complete Response Letter is the expected outcome. Duchenne muscular dystrophy affects approximately 20,000 US patients (predominantly boys with X-linked inheritance) and progressive cardiomyopathy is the leading cause of death in the population. The DMD cardiomyopathy indication remains without an FDA-approved therapy.

#capricor-therapeutics #capr #deramiocel #duchenne-muscular-dystrophy #dmd-cardiomyopathy #pdufa-target-action-date #hope-3 #cell-therapy #complete-response-letter #adcom-9-3-vote #lvef-endpoint #statistical-instability

Regulatory

Hengrui Pharma Disclosed Saturday August 22, 2026 That China's Center for Drug Evaluation (CDE) Granted Implied License for HRS-4729 in Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) and Hepatitis, Extending Hengrui's Cardiometabolic Pipeline Beyond Its Existing Ribupatide (GLP-1/GIP/Glucagon Triple Agonist Licensed Ex-China to Kailera Therapeutics for Global Phase 3 in H1 2027) Into the Growing MASH Commercial Category That Is Anchored Commercially by Madrigal Pharmaceuticals' Rezdiffra (Resmetirom, First MASH Drug Approved March 2024) and Novo Nordisk's Wegovy (Semaglutide 2.4 mg, First GLP-1 Receptor Agonist Approved for MASH in August 2025); The Hengrui CDE Implied License Provides Approval to Initiate Human Clinical Trials in China Under a Simplified Regulatory Pathway

Hengrui Pharma disclosed Saturday August 22, 2026 that China's Center for Drug Evaluation (CDE) granted implied license for HRS-4729 in metabolic dysfunction-associated fatty liver disease (MAFLD) and hepatitis. The CDE implied license is a Chinese regulatory instrument that provides approval to initiate human clinical trials in China under a simplified pathway (similar in function to a US Investigational New Drug application, though procedurally different). HRS-4729's specific molecular mechanism has not been publicly disclosed in detail; the MAFLD/hepatitis indication placement suggests likely mechanisms include FGF21 analog, thyroid hormone receptor beta agonist, or a novel liver-target mechanism. The disclosure extends Hengrui's cardiometabolic pipeline beyond its existing ribupatide (once-weekly injectable GLP-1/GIP/glucagon triple agonist licensed ex-China to Kailera Therapeutics for global Phase 3 initiation in H1 2027) into the growing MASH commercial category. MASH commercial market context: the category is anchored by Madrigal Pharmaceuticals' Rezdiffra (resmetirom, a thyroid hormone receptor beta agonist and the first FDA-approved MASH drug, approved March 2024) and Novo Nordisk's Wegovy (semaglutide 2.4 mg received FDA accelerated approval for non-cirrhotic MASH with moderate-to-advanced fibrosis in August 2025). The Hengrui advance into MAFLD/hepatitis positions the company for a potential fourth cardiometabolic franchise beyond obesity, type 2 diabetes, and cardiovascular disease.

#hengrui-pharma #hrs-4729 #cde-implied-license #mafld #hepatitis #mash-commercial-category #rezdiffra #resmetirom #wegovy-mash #madrigal-pharmaceuticals #cardiometabolic-pipeline #chinese-cde